<DOC>
	<DOC>NCT01559077</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-TTR02 in healthy volunteer subjects.</brief_summary>
	<brief_title>Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Body mass index must be between 18.0 kg/m2 and â‰¤ 31.5 kg/m2; Nonsmokers for at least 3 months preceding screening; Females subjects must be of nonchildbearing potential e.g., postmenopausal or premenopausal with surgical sterilization; Males agree to use appropriate contraception; Medical history must be verified by either a personal physician or medical practitioner as appropriate; Willing to give written informed consent and are willing to comply with the study requirements. Known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection Multiple drug allergies or know sensitivity to oligonucleotide History of drug abuse and/or alcohol abuse Receiving an investigational agent within 3 months prior to study drug administration Subjects with safety laboratory test results deemed clinical significant by the Investigator; Received prescription drugs within 4 weeks of first dosing Subjects who have donated more than 500 mL of blood within the 3 months prior to ALNPCS02 or placebo administration; Subjects who have used prescription drugs within 4 weeks of first dosing Considered unfit for the study by the Principal Investigator Employee or family member of the sponsor or the clinical study site personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>ATTR</keyword>
</DOC>